---
figid: PMC3775637__cmar-5-251Fig3
figlink: /pmc/articles/PMC3775637/figure/f3-cmar-5-251/
number: Figure 3
caption: 'Targeting the PI3K and BTK pathways in NHL. The B-cell receptor-signaling
  pathway (purple) is initiated through phosphorylation of coreceptors that recruit
  spleen tyrosine kinase (SYK), which then phosphorylates downstream kinases, including
  PLCγ, leading to activation of Bruton tyrosine kinase (BTK). BTK then binds phosphatidylinositol
  (3,4,5)-triphosphate (PIP3), which in turn hydrolyzes phosphatidylinositol 4,5-bisphosphate
  (PIP2) into two second messengers – inositol triphosphate (IP3) and diacylglycerol
  (DAG) – that ultimately activate downstream proteins involved in B-cell signaling.
  In the PI3K pathway (orange), activation of receptor tyrosine kinases (RTKs) through
  adaptor proteins phosphorylate subunits of PI3K, leading to conversion of PIP2 to
  PIP3. Phosphorylation of the tumor suppressor PTEN terminates PI3K. Accumulation
  of PIP3 leads to phosphorylation of AKT, which further activates downstream pathways,
  including mTOR (through the tuberous sclerosis complex 1/2 (TSC1/2)) and other essential
  pathways. Therapeutic inhibition of select pathway components that have been investigated
  in clinical trials for NHL are shown.Abbreviations: 4EBP-1, 4E-binding protein 1;
  GSK3, glycogen synthase kinase 3; mTOR, mammalian target of rapamycin; mTORC, mTOR
  complex; MDM2, mouse double minute 2 homolog; P, phosphorylation site; PI3K, phosphoinositide
  3-kinase; PLC, phospholipase C gamma; PTEN, phosphatase and tensin homolog; RHEB,
  Ras homolog enriched in brain; S6K, S6 kinase.'
pmcid: PMC3775637
papertitle: Treatment challenges in the management of relapsed or refractory non-Hodgkin’s
  lymphoma – novel and emerging therapies.
reftext: Mark P Chao. Cancer Manag Res. 2013;5:251-269.
pmc_ranked_result_index: '176717'
pathway_score: 0.9613406
filename: cmar-5-251Fig3.jpg
figtitle: Targeting the PI3K and BTK pathways in NHL
year: '2013'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3775637__cmar-5-251Fig3.html
  '@type': Dataset
  description: 'Targeting the PI3K and BTK pathways in NHL. The B-cell receptor-signaling
    pathway (purple) is initiated through phosphorylation of coreceptors that recruit
    spleen tyrosine kinase (SYK), which then phosphorylates downstream kinases, including
    PLCγ, leading to activation of Bruton tyrosine kinase (BTK). BTK then binds phosphatidylinositol
    (3,4,5)-triphosphate (PIP3), which in turn hydrolyzes phosphatidylinositol 4,5-bisphosphate
    (PIP2) into two second messengers – inositol triphosphate (IP3) and diacylglycerol
    (DAG) – that ultimately activate downstream proteins involved in B-cell signaling.
    In the PI3K pathway (orange), activation of receptor tyrosine kinases (RTKs) through
    adaptor proteins phosphorylate subunits of PI3K, leading to conversion of PIP2
    to PIP3. Phosphorylation of the tumor suppressor PTEN terminates PI3K. Accumulation
    of PIP3 leads to phosphorylation of AKT, which further activates downstream pathways,
    including mTOR (through the tuberous sclerosis complex 1/2 (TSC1/2)) and other
    essential pathways. Therapeutic inhibition of select pathway components that have
    been investigated in clinical trials for NHL are shown.Abbreviations: 4EBP-1,
    4E-binding protein 1; GSK3, glycogen synthase kinase 3; mTOR, mammalian target
    of rapamycin; mTORC, mTOR complex; MDM2, mouse double minute 2 homolog; P, phosphorylation
    site; PI3K, phosphoinositide 3-kinase; PLC, phospholipase C gamma; PTEN, phosphatase
    and tensin homolog; RHEB, Ras homolog enriched in brain; S6K, S6 kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R3
  - PIK3CD
  - PIK3CA
  - PIK3CG
  - RPTOR
  - PLCG2
  - PIK3CB
  - MTOR
  - TSC2
  - PIK3R6
  - PIK3R4
  - RICTOR
  - TP53
  - TSC1
  - PIK3R5
  - SART3
  - MDM2
  - MLST8
  - PLCG1
  - RHEB
  - MYC
  - SYK
  - GSK3A
  - GSK3B
  - MAPKAP1
  - AKT2
  - BTK
  - PTEN
  - AKT1
  - AKT3
  - EIF4EBP1
  - Perifosine
  - Temsirolimus
  - Fostamatinib
  - Ibrutinib
  - Sirolimus
  - Cancer
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: PLCY
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: TSC2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: TSC1
  symbol: TSC1
  source: hgnc_symbol
  hgnc_symbol: TSC1
  entrez: '7248'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: p110
  symbol: p110
  source: hgnc_alias_symbol
  hgnc_symbol: SART3
  entrez: '9733'
- word: MDM2
  symbol: MDM2
  source: hgnc_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: PLCY
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RHEB
  symbol: RHEB
  source: hgnc_symbol
  hgnc_symbol: RHEB
  entrez: '6009'
- word: Myc
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: SYK
  symbol: SYK
  source: hgnc_symbol
  hgnc_symbol: SYK
  entrez: '6850'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3A
  entrez: '2931'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: BTK
  symbol: BTK
  source: hgnc_symbol
  hgnc_symbol: BTK
  entrez: '695'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: 4EBP-1
  symbol: 4E-BP1
  source: hgnc_alias_symbol
  hgnc_symbol: EIF4EBP1
  entrez: '1978'
chemicals:
- word: Perifosine
  source: MESH
  identifier: C105905
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Fostamatinib
  source: MESH
  identifier: C523665
- word: Ibrutinib
  source: MESH
  identifier: C551803
- word: Sirolimus
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
